News
Voluntary Recall of Zantac by Sanofi/FDA
Sanofi has initiated a voluntary recall of all Zantac OTC (over-the-counter) products in the United States. This includes Zantac 150®, Zantac 150® Cool Mint, and Zantac 75®.
FDA Approves Ustekinumab for Ulcerative Colitis
Ustekinumab (Stelara) is now FDA-approved to treat moderately to severely active ulcerative colitis, said drugmaker Janssen on Monday, in addition to its indications for psoriasis, psoriatic arthritis, and Crohn's disease.
Pain Persists Despite TNF Inhibitor Use
Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain.
Adalimumab and Pregnancy Outcomes
A prospective study of birth outcomes to mothers exposed to adalimumab (ADA) between 2004 and 2016 was conducted by Organization of Teratology Information Specialists (OTIS) Research Center at the University of California San Diego, and showed that ADA exposure was not associated with an increase
Interleukin Targeted Biologics Increase Risks of Infection
A systematic review of the literature shows that, compared to placebo, the use of non-TNF, interleukin inhibitor biologics may be associated with significantly higher rates of serious infections, opportunistic infections, and cancer.
Comorbidities Increase in Importance in RA
Patients with rheumatoid arthritis (RA) have a large comorbidity burden at the time of diagnosis, including a wide range of ailments but with pulmonary disease a particular concern, a U.K. population-based study found.
RheumNow Podcast – Fight or Switching (DMARDs) (10.18.19)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Joint Injections: Are They Worth the Risk?
Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.
Protective Effects of ASA and Vasodilators in Systemic Sclerosis
A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable cardiovascular outcomes.
High Dose Statins Increase Odds of Osteoporosis
It is unknown if inhibiting cholesterol synthesis (with statins) might influence sex-hormone production and therefore, the risk of osteoporosis. A new study shows that, in statin-treated individuals, the development of osteoporosis is statin dose-dependent.
